| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S0033291718002465 |
| P698 | PubMed publication ID | 30180918 |
| P50 | author | Robert W. Buchanan | Q109937282 |
| P2093 | author name string | Deanna L Kelly | |
| Gregory P Strauss | |||
| James M Gold | |||
| Eric Granholm | |||
| Jason L Holden | |||
| Ivan Ruiz | |||
| P2860 | cites work | Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients | Q24643290 |
| Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy | Q26863704 | ||
| A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis | Q27320111 | ||
| Oxytocin increases trust in humans | Q28254266 | ||
| Modulating social behavior with oxytocin: how does it work? What does it mean? | Q28730932 | ||
| The social brain: neural basis of social knowledge | Q28756480 | ||
| Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits | Q30492008 | ||
| Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task | Q47819695 | ||
| A single dose of oxytocin nasal spray improves higher-order social cognition in schizophrenia | Q48091874 | ||
| Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia | Q48154990 | ||
| A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia | Q48300211 | ||
| Effects of single dose intranasal oxytocin on social cognition in schizophrenia. | Q48474567 | ||
| Visual scanpaths to positive and negative facial emotions in an outpatient schizophrenia sample | Q48630184 | ||
| Improving social perception in schizophrenia: the role of oxytocin. | Q50536020 | ||
| Personality-dependent effects of oxytocin: greater social benefits for high alexithymia scorers. | Q50625713 | ||
| Modification of affect perception deficits in schizophrenia. | Q51072061 | ||
| Post-learning intranasal oxytocin modulates human memory for facial identity. | Q51966380 | ||
| Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. | Q52207888 | ||
| The "Reading the Mind in the Eyes" Test Revised Version: A Study with Normal Adults, and Adults with Asperger Syndrome or High-functioning Autism | Q55879677 | ||
| A depression rating scale for schizophrenics | Q68663014 | ||
| The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients | Q68680780 | ||
| Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia | Q84759806 | ||
| Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties | Q30550244 | ||
| Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies | Q30577718 | ||
| Oxytocin-augmented social cognitive skills training in schizophrenia | Q33923629 | ||
| Oxytocin improves specific recognition of positive facial expressions | Q34100753 | ||
| Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics | Q34257617 | ||
| Peripheral oxytocin is associated with reduced symptom severity in schizophrenia | Q34311629 | ||
| Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders | Q34322999 | ||
| Oxytocin improves "mind-reading" in humans | Q34586095 | ||
| Best practices: The development of the Social Cognition and Interaction Training program for schizophrenia spectrum disorders | Q34616441 | ||
| Oxytocin increases gaze to the eye region of human faces | Q34691878 | ||
| Oxytocin enhances the encoding of positive social memories in humans | Q34761999 | ||
| Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome | Q34776902 | ||
| Oxytocin shapes the neural circuitry of trust and trust adaptation in humans | Q34781060 | ||
| Oxytocin administration enhances controlled social cognition in patients with schizophrenia | Q34790823 | ||
| Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia | Q35115758 | ||
| Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. | Q35116515 | ||
| Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia | Q35117441 | ||
| Endogenous oxytocin levels are associated with the perception of emotion in dynamic body expressions in schizophrenia | Q35118062 | ||
| Implications for the Neural Basis of Social Cognition for the Study of Schizophrenia | Q35120014 | ||
| Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis | Q36756329 | ||
| Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia | Q36767785 | ||
| Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia | Q36821775 | ||
| Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications | Q36950108 | ||
| Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities | Q37053979 | ||
| A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions | Q37977739 | ||
| Intranasal Oxytocin: Myths and Delusions | Q38517964 | ||
| Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis | Q38674187 | ||
| Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward | Q38683538 | ||
| A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder | Q39999374 | ||
| Oxytocin to modulate emotional processing in schizophrenia: A randomized, double-blind, cross-over clinical trial. | Q40621302 | ||
| Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism | Q41256682 | ||
| Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol | Q44590480 | ||
| It takes two: the interpersonal nature of empathic accuracy. | Q44757202 | ||
| Friend or foe: the effect of implicit trustworthiness judgments in social decision-making | Q45152041 | ||
| Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls. | Q45972914 | ||
| Intranasal Oxytocin Mechanisms Can Be Better Understood, but Its Effects on Social Cognition and Behavior Are Not to Be Sniffed At. | Q46131530 | ||
| Revisiting non-significant effects of intranasal oxytocin using equivalence testing | Q47590158 | ||
| Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis. | Q47654641 | ||
| P433 | issue | 10 | |
| P921 | main subject | schizophrenia | Q41112 |
| social cognition | Q1432778 | ||
| P304 | page(s) | 1731-1739 | |
| P577 | publication date | 2018-09-05 | |
| P1433 | published in | Psychological Medicine | Q7256364 |
| P1476 | title | The effects of combined oxytocin and cognitive behavioral social skills training on social cognition in schizophrenia | |
| P478 | volume | 49 |
| Q90259423 | Conclusions and questions from a non-randomised comparison of routine clinical services implementing different treatment models for borderline personality disorder | cites work | P2860 |
Search more.